The Government of Georgia has amended its pharmaceutical regulations, allowing wholesale distributors to continue selling certain medicines beyond previously given deadlines. Under earlier rules, effective October 1, 2025, all pharmaceuticals registered in Georgia were required to hold a ‘Good Manufacturing Practice’ certificate confirming compliance with international production standards. Distributors had been given until April 1, 2026, to sell off existing stock that did not meet the new requirements.
Following amendments to Resolution No. 114 (adopted March 4, 2022), distributors, excluding imported products, are now permitted to sell remaining inventories until their expiration dates. The change also allows the continued sale, both wholesale and retail, of registered medicines whose status had been affected under the previous regulation.
The policy adjustment comes after industry representatives, including the Pharmaceutical Association of Georgia, raised concerns that companies would be unable to fully clear their inventories within the original timeline.
Despite the relaxation, stricter standards remain in place for new products. All medicines registered or re-registered in Georgia from October 1, 2025, must be accompanied by GMP certification covering both the finished product and the substances used in its production. This requirement applies equally to local manufacturers and distributors.
